SEC Form 4 · accession 0001237899-18-000010
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marion McCourt
Officer — SVP Commercial
Period of report
Feb 12, 2018
Accepted (ET)
Feb 12, 2018 · 5:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 12, 2018 | A | 2,500 | $0.00 | A | 2,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $342.93 | Feb 12, 2018 | A | 20,000 | A | — | Feb 12, 2028 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1Award of Restricted Stock under the Amended and Restated 2014 Long-Term Incentive Plan that vests in its entirety on February 12, 2023.
- F2The stock option award vests in four equal annual installments, commencing one year after the date of grant.